Ligand Pharmaceuticals (LGND) Short-term Investments (2010 - 2026)

Ligand Pharmaceuticals has disclosed Short-term Investments across 17 years of filings, most recently posting $664.3 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $664.3 million, up 312.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $664.3 million (up 312.85% YoY), and the FY2025 annual result was $15.6 million, down 91.5% from the prior year.
• Short-term Investments came in at $664.3 million for Q1 2026 at Ligand Pharmaceuticals, up from $15.6 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $664.3 million in Q1 2026 to a low of $11.1 million in Q3 2024.
• The 5-year median for Short-term Investments is $177.4 million (2025), against an average of $207.4 million.
• Across the five-year window, Short-term Investments tumbled 93.5% in 2024 and surged 4617.02% in 2025, its largest moves.
• Ligand Pharmaceuticals' Short-term Investments stood at $166.9 million in 2022, then fell by 11.69% to $147.4 million in 2023, then rose by 24.77% to $183.9 million in 2024, then plunged by 91.5% to $15.6 million in 2025, then jumped by 4149.8% to $664.3 million in 2026.
• The last three Short-term Investments figures came in at $664.3 million (Q1 2026), $15.6 million (Q4 2025), and $525.1 million (Q3 2025), per Business Quant data.